Aurinia Pharmaceuticals INC 10-Q quarterly reports

Aurinia Pharmaceuticals Inc. announced significant revenue growth for LUPKYNIS and a substantial increase in operating cash flow for the second quarter of 2026.

Aurinia Pharmaceuticals Inc. announced a significant increase in net product sales and improved operating income for the first quarter of 2026, driven by strong performance of LUPKYNIS.

Aurinia Pharmaceuticals Inc. announced significant increases in net product sales and net income for the third quarter and first nine months of 2025, driven by LUPKYNIS growth and strategic restructuring benefits.

Aurinia Pharmaceuticals Inc. announced a significant swing to profitability and robust revenue growth for the second quarter and first half of 2025, driven by increased LUPKYNIS sales and strategic cost reductions, alongside positive clinical data for its pipeline asset and an expanded share repurchase plan.

Aurinia Pharmaceuticals announces a 25% increase in net product sales for Q1 2025, driven by growing Lupkynis sales and market penetration.

Aurinia Pharmaceuticals reported its Q3 2024 financial results, highlighted by increased product revenue and a strategic restructuring aimed at focusing on LUPKYNIS growth and AUR200 development.

Aurinia Pharmaceuticals saw a significant increase in revenue in the second quarter of 2024, driven by higher sales of LUPKYNIS and a strategic restructuring.

Aurinia Pharmaceuticals reported its Q1 2024 results, highlighting a strategic shift towards commercializing LUPKYNIS, alongside a corporate restructuring to enhance shareholder value.